Journal article

Prostate cancer screening with prostate-specific antigen: A guide to the guidelines

Sonja Cabarkapa, Marlon Perera, Shannon McGrath, Nathan Lawrentschuk

Prostate International | ELSEVIER INC | Published : 2016


BACKGROUND: Prostate cancer remains the most common non-skin cancer malignancy in men. Prostate-specific antigen (PSA) is recognized as a biomarker for the diagnosis, monitoring, and risk prediction of prostate cancer. Its use in the setting of prostate cancer screening has been controversial due to the risk of over diagnosis and over treatment. OBJECTIVE: Within Australia, there are inconsistent recommendations surrounding the use of PSA screening in clinical practice. In light of the 2016 PSA-screening guidelines by the major Australian health authorities, the current review aims to highlight the controversies and objectively outline the current recommendations within Australia. DISCUSSION..

View full abstract